EARLY Trial
The EARLY Trial was looking to determine the Efficacy and safety of atabecestat in participants who are Asymptomatic at Risk for developing Alzheimer’s dementia. The study sponsor, Janssen, sought to use the latest advances to assess a participant’s risk associated with beta-amyloid and memory loss, and test whether a treatment that reduces amyloid formation would slow memory loss associated with Alzheimer’s disease (AD).
Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD)
Those identified to have a potential increased risk for memory loss caused by Alzheimer’s disease were referred from the APT Webstudy (above) to the Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD) in-person study. The purpose of TRC-PAD was to find as many people as possible (also called a “cohort”) who were interested in participating in clinical trials aimed at discovering treatments to reduce the risk of developing Alzheimer’s dementia. TRC-PAD sought to help researchers enroll participants into these trials quickly to allow new treatments to be discovered as soon as possible.